Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey.

ABSTRACT:

Background

In acute lymphoblastic leukemia (ALL), the presence of minimal residual disease (MRD) after induction/consolidation chemotherapy is a strong prognostic factor for subsequent relapse and mortality. Accordingly, European clinical guidelines and protocols recommend testing patients who achieve a complete hematological remission (CR) for MRD for the purpose of risk stratification. The aim of this study was to provide quantitative information regarding real-world clinical practice for MRD testing in five European countries.

Methods

A web-based survey was conducted in March/April 2017 in France, Germany, Italy, Spain, and the UK. The survey was developed after consultation with specialist clinicians and a review of published literature. Eligible clinicians (20 per count

SUBMITTER: Pigneux A 

PROVIDER: S-EPMC6233570 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature